| Description |
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research[1][2][3].
|
| Related Catalog |
|
| Target |
SDF-1α-CXCR4
|
| In Vitro |
CTCE-0214 (0.01-0.1 ng/mL; 4 d) increases the expansion of CD34+ cells subsets[3].
|
| In Vivo |
CTCE-0214 (intravenous injection; 1-25 mg/kg; once) treatment inhibits Lipopolysaccharide-induced plasma TNF-α production[1]. CTCE-0214 (intraperitoneal injection and intravenous injection; 25 mg/kg; once) decreases Zymosan-induced plasma TNF-α production[1]. Animal Model: Male CD-1 mice injected with Lipopolysaccharide[1] Dosage: 1, 10, or 25 mg/kg Administration: Intravenous injection; 1, 10, or 25 mg/kg; once Result: Decreased LPS-induced plasma TNF-α production in a dose dependent manor with a 93% reduction. Showed no significant effect on LPS-induced plasma IL-6 and IL-10 production. Animal Model: Zymosan-induced peritonitis mice model[1] Dosage: 25 mg/kg Administration: Intraperitoneal injection and intravenous injection; 25 mg/kg; once Result: Showed a significant reduction in plasma TNF-α (53 reduction, p<0.05).
|
